REPROCELL is joining a consortium with North American and European partners to develop a novel mRNA vaccine against CoV-2. REPROCELL and the other partners have extensive experience in the mRNA vaccine field which will help accelerate progress towards clinical trials with patient enrolment expected in early 2021!

read more